Enzo Biochem Inc ENZ
We take great care to ensure that the data presented and summarized in this overview for ENZO BIOCHEM INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENZ
View all-
Harbert Fund Advisors, Inc. Birmingham, AL5.18MShares$5.59 Million3.43% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.53MShares$2.73 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$2.03 Million0.0% of portfolio
-
Potomac Capital Management, Inc.1.48MShares$1.6 Million3.63% of portfolio
-
Viex Capital Advisors, LLC Sunny Isles Beach, FL1.33MShares$1.44 Million9.62% of portfolio
-
Black Rock Inc. New York, NY955KShares$1.03 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA369KShares$398,1370.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX304KShares$328,8510.0% of portfolio
-
Rbf Capital, LLC San Francisco, CA250KShares$270,3870.01% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX181KShares$195,2640.0% of portfolio
Latest Institutional Activity in ENZ
Top Purchases
Top Sells
About ENZ
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ?STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Insider Transactions at ENZ
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 24
2024
|
Kara Cannon Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
70,885
-15.71%
|
$70,885
$1.17 P/Share
|
Feb 23
2024
|
Kara Cannon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+24.95%
|
-
|
Feb 21
2024
|
Kara Cannon Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,823
-1.9%
|
-
|
Feb 21
2024
|
Kara Cannon Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,640
+3.35%
|
-
|
Jan 31
2024
|
Bradley Louis Radoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
79,365
+1.78%
|
-
|
Jan 31
2024
|
Mary Tagliaferri Director |
BUY
Grant, award, or other acquisition
|
Direct |
79,365
+20.26%
|
-
|
Jan 31
2024
|
Steven J Pully Director |
BUY
Grant, award, or other acquisition
|
Direct |
79,365
+44.98%
|
-
|
Oct 30
2023
|
Steven J Pully Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,730
+50.0%
|
-
|
Aug 31
2023
|
Kara Cannon Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
63,700
-17.69%
|
$63,700
$1.54 P/Share
|
Aug 31
2023
|
Kara Cannon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
345,080
+48.93%
|
-
|
Feb 13
2023
|
Ian B. Walters Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,188
+32.53%
|
-
|
Feb 13
2023
|
James G. Wolf |
BUY
Open market or private purchase
|
Indirect |
5,000
+4.17%
|
$5,000
$1.29 P/Share
|
Feb 13
2023
|
James G. Wolf |
BUY
Open market or private purchase
|
Direct |
5,000
+0.12%
|
$5,000
$1.28 P/Share
|
Feb 10
2023
|
James G. Wolf |
BUY
Open market or private purchase
|
Direct |
5,000
+0.12%
|
$5,000
$1.29 P/Share
|
Feb 09
2023
|
Bradley Louis Radoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,188
+1.71%
|
-
|
Feb 09
2023
|
Mary Tagliaferri Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,188
+32.53%
|
-
|
Jan 27
2023
|
James G. Wolf |
BUY
Open market or private purchase
|
Direct |
11,800
+0.29%
|
$11,800
$1.4 P/Share
|
Jan 23
2023
|
James G. Wolf |
BUY
Conversion of derivative security
|
Direct |
263,200
+3.1%
|
$789,600
$3.75 P/Share
|
Dec 28
2022
|
Kara Cannon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,600
+45.49%
|
-
|
Dec 16
2022
|
James G. Wolf |
BUY
Conversion of derivative security
|
Direct |
33,700
+0.88%
|
$67,400
$2.5 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 388K shares |
---|---|
Exercise of conversion of derivative security | 10.6K shares |
Payment of exercise price or tax liability | 76.7K shares |
---|